"Retreatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
Descriptor ID |
D019233
|
MeSH Number(s) |
E02.887
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Retreatment".
Below are MeSH descriptors whose meaning is more specific than "Retreatment".
This graph shows the total number of publications written about "Retreatment" by people in this website by year, and whether "Retreatment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 2 | 2 |
2000 | 0 | 2 | 2 |
2001 | 0 | 4 | 4 |
2002 | 0 | 2 | 2 |
2004 | 0 | 4 | 4 |
2005 | 0 | 2 | 2 |
2006 | 0 | 2 | 2 |
2007 | 0 | 9 | 9 |
2008 | 0 | 6 | 6 |
2009 | 1 | 10 | 11 |
2010 | 0 | 13 | 13 |
2011 | 0 | 11 | 11 |
2012 | 0 | 7 | 7 |
2013 | 0 | 4 | 4 |
2014 | 0 | 5 | 5 |
2015 | 0 | 17 | 17 |
2016 | 0 | 17 | 17 |
2017 | 0 | 25 | 25 |
2018 | 0 | 17 | 17 |
2019 | 0 | 12 | 12 |
2020 | 1 | 8 | 9 |
2021 | 0 | 7 | 7 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Retreatment" by people in Profiles.
-
Retreatment of Residual and Recurrent Aneurysms After Embolization With the Woven EndoBridge Device: Multicenter Case Series. Neurosurgery. 2022 05 01; 90(5):569-580.
-
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 07; 21(1):904.
-
Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series. Pediatr Rheumatol Online J. 2021 Jun 07; 19(1):84.
-
A morphovolumetric analysis of aneurysm sac evolution after elective endovascular abdominal aortic repair. J Vasc Surg. 2021 10; 74(4):1222-1231.e2.
-
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clin Cancer Res. 2021 05 15; 27(10):2742-2754.
-
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
-
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 2021 03 01; 39(7):807-821.
-
Bridging Stents in Fenestrated and Branched Endovascular Aneurysm Repair: A Systematic REVIEW. Ann Vasc Surg. 2021 May; 73:454-462.
-
Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest. 2021 03; 159(3):1256-1264.
-
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. Br J Haematol. 2020 11; 191(3):e77-e81.